Table 1.
Patient characteristics.
| Patient | Sex | Age | IgGNMDA receptor antibodies (CSF titer) | Symptoms | Duration of unconsciousness, day | Treatment protocol | Hospital stay month | Paraneoplastic syndrome | mRS score | AEDs at study time point | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial | Total | Tumor | Resection | Before treatment | Study time point | ||||||||
| 1 | F | 22 | 1:32 | Behavior, seizure | LOC, dyskinesia, seizure, behavior, cognition | 15–20 | High‐dose steroids, IVIG, cyclophosphamide | 1.1 | None | / | 5 | 0 | Topiramate 50 mg/day |
| 2 | M | 28 | 1:32 | Behavior, dyskinesia | LOC, dyskinesia, seizure, behavior, cognition, autonomic instability | 20–25 | High‐dose steroids, IVIG, cyclophosphamide | 1.2 | None | / | 5 | 1 | None |
| 3 | M | 31 | 1:32 | Seizure, LOC | LOC, dyskinesia, seizure, behavior, cognition, autonomic instability | 25–30 | IVIG, cyclophosphamide | 1.4 | None | / | 5 | 0 | None |
| 4 | F | 15 | 1:32 | Dyskinesia, seizure | Dyskinesia, seizure, behavior, cognition | NA | High‐dose steroids, IVIG, rituximab | 1.2 | None | / | 4 | 1 | Oxcarbazepine 900 mg/day |
| 5 | F | 24 | 1:32 | Behavior | LOC, dyskinesia, seizure, behavior, cognition | 10–15 | High‐dose steroids, IVIG, cyclophosphamide | 1.2 | None | / | 5 | 0 | None |
| 6 | F | 34 | 1:32 | Behavior, cognition | LOC, dyskinesia, seizures, behavior, cognition, autonomic instability | 700+ | High‐dose steroids, plasmapheresis, IVIG, rituximab, cyclophosphamide | 26 | Mature cystic teratoma of left ovarian | yes | 5 | 0 | None |
| 7 | M | 22 | 1:32 | Behavior | LOC, dyskinesia, seizures, behavior, cognition | 10–15 | Cyclophosphamide | 0.8 | None | / | 4 | 0 | None |
| 8 | F | 25 | 1:32 | Behavior, seizure | LOC, dyskinesia, seizures, behavior, cognition | 20–25 | High‐dose steroids, IVIG, rituximab, cyclophosphamide | 1.2 | Mature cystic teratoma of bilateral ovarian | yes | 5 | 0 | None |
| 9 | F | 20 | 1:32 | Behavior, dyskinesia | LOC, dyskinesia, seizures, behavior, cognition | 20–25 | High‐dose steroids, IVIG, rituximab, cyclophosphamide | 1.3 | None | / | 5 | 2 | None |
| 10 | F | 30 | 1:32 | Behavior | LOC, behavior, cognition | 8–10 | High‐dose steroids, IVIG | 0.7 | None | / | 4 | 0 | None |
| 11 | M | 49 | 1:10 | Seizure, behavior | LOC, dyskinesia, seizure, behavior, cognition | 15–20 | High‐dose steroids, IVIG | 1.2 | None | / | 5 | 1 | None |
| 12 | F | 34 | 1:10 | Dyskinesia, cognition | Dyskinesia, behavior, cognition | NA | High‐dose steroids, IVIG | 0.8 | None | / | 4 | 0 | None |
| 13 | F | 42 | 1:10 | Seizure, behavior, | LOC, seizure, behavior, cognition, autonomic instability | 20–25 | High‐dose steroids, IVIG | 1.2 | None | / | 5 | 1 | None |
| 14 | F | 25 | 1:32 | Seizure, behavior, | Seizure, behavior, cognition | NA | High‐dose steroids, IVIG | 1.3 | Mature cystic teratoma of right ovarian | yes | 5 | 0 | None |
| 15 | M | 22 | 1:32 | Behavior, seizure | LOC, seizure, behavior, cognition | 20–25 | High‐dose steroids, IVIG | 1.3 | None | / | 4 | 0 | None |
| 16 | F | 52 | 1:32 | Behavior, seizure | Seizure, behavior, cognition | NA | High‐dose steroids, IVIG | 1.2 | None | / | 4 | 1 | None |
CSF, cerebrospinal fluid; LOC, loss of consciousness; IVIG, intravenous human immunoglobulin; mRS, modified Rankin Score; AEDs, antiepileptic drugs; NA, not applicable.